There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medtronic (MDT) and Crispr Therapeutics AG (CRSP) with bullish sentiments.
Medtronic (MDT)
Needham analyst Michael Matson reiterated a Buy rating on Medtronic today and set a price target of $134.00. The company’s shares closed last Monday at $111.25, close to its 52-week high of $114.46.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.2% and a 62.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Medtronic has an analyst consensus of Strong Buy, with a price target consensus of $117.53.
See today’s analyst top recommended stocks >>
Crispr Therapeutics AG (CRSP)
In a report released today, Raju Prasad from William Blair upgraded Crispr Therapeutics AG to Buy. The company’s shares closed last Monday at $68.42, close to its 52-week high of $74.00.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 13.8% and a 53.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $73.81 average price target, which is a 19.0% upside from current levels. In a report issued on November 12, Oppenheimer also upgraded the stock to Buy with a $65.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
